Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
- Conditions
- Brain and Central Nervous System TumorsExtragonadal Germ Cell TumorTesticular Germ Cell Tumor
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 47
- Registration Number
- NCT01172912
- Locations
- 🇮🇹
Fondazione Istituto Nazionale dei Tumori, Milan, Italy
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
- Conditions
- Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01169636
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin Lymphoma
- Interventions
- Drug: Bendamustine HydrochlorideDrug: CarboplatinBiological: RituximabDrug: EtoposideOther: Laboratory Biomarker Analysis
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 48
- Registration Number
- NCT01165112
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 11
- Registration Number
- NCT01154439
- Locations
- 🇮🇹
Università La Sapienza, Roma, Italy
🇮🇹Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy
Autologous Transplant in HIV Patients (BMT CTN 0803)
- Conditions
- HIVLymphoma
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 43
- Registration Number
- NCT01141712
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸University of CA, SF, San Francisco, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 610
- Registration Number
- NCT01134861
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
- Interventions
- Drug: bortezomibDrug: mitoxantrone hydrochlorideDrug: etoposideDrug: cytarabineOther: flow cytometry
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01127009
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: PEG-L-asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mercaptopurineDrug: ifosfamideDrug: methotrexateDrug: vincristine sulfateDrug: prednisoneRadiation: Radiation TherapyDrug: thioguanineDrug: vindesineDrug: daunoxomeDrug: fludarabine
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 6136
- Registration Number
- NCT01117441
- Locations
- 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
- Conditions
- Nodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic Lymphoma
- Interventions
- Drug: bendamustine hydrochlorideDrug: dexamethasoneBiological: filgrastimProcedure: leukapheresisOther: laboratory biomarker analysisOther: flow cytometryDrug: etoposide
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 43
- Registration Number
- NCT01110135
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 31
- Registration Number
- NCT01104025
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.